Tags

Type your tag names separated by a space and hit enter

Treatment of rat adjuvant arthritis with flavonoid (Detralex), methotrexate, and their combination.
Ann N Y Acad Sci. 2009 Sep; 1173:798-804.AN

Abstract

In both adjuvant arthritis and rheumatoid arthritis, edema and inflammation appear in synovial joints. Edema or effusion reflects an imbalance in lymph dynamics. Purified micronized flavonoid fraction is mainly used in the treatment of chronic venous insufficiency. This compound improves lymphatic drainage with a significant increase in lymphatic flow and lymphatic pulsality. It is suggested that the beneficial effect of purified micronized flavonoid fraction may be involved in the treatment of adjuvant arthritis in rats. In this study treatment of adjuvant arthritis in rats with Detralex, methotrexate, and their combination were evaluated. Groups of rats with adjuvant arthritis were treated with methotrexate (0.6 mg/kg/week), Detralex (20 mg/kg/day), and their combination for 50 days from adjuvant application. Hind paw swelling, arthrogram scores, serum albumin level, serum nitrite/nitrate concentrations, and whole-body mineral density were evaluated as markers of inflammation and destructive changes associated with arthritis. Long-term prophylactic treatment with low-dose methotrexate significantly inhibited the markers of both inflammation and arthritis. Detralex administered alone slightly decreased both the hind paw swelling and the arthritic score. Other inflammatory and arthritic markers were not significantly influenced. However, Detralex combined with methotrexate markedly potentiated the beneficial effects of methotrexate, which resulted in a more significant reduction in hind paw swelling, arthritic scores, and serum concentrations of nitrite/nitrate. Interestingly, the arthritis-induced decrease of bone mineral density in AA rats was significantly lower only in the group treated with the combination of Detralex and methotrexate. Our results indicate that Detralex increased the therapeutic efficacy of methotrexate basal treatment in AA. We suggest that this may be related to the beneficial effect of Detralex on microcirculation, especially on venules and lymphatic vessels.

Authors+Show Affiliations

National Institute of Rheumatic Diseases, Piest'any, Slovak Republic. rovensky@nurch.skNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

19758231

Citation

Rovenský, Jozef, et al. "Treatment of Rat Adjuvant Arthritis With Flavonoid (Detralex), Methotrexate, and Their Combination." Annals of the New York Academy of Sciences, vol. 1173, 2009, pp. 798-804.
Rovenský J, Stancíková M, Rovenská E, et al. Treatment of rat adjuvant arthritis with flavonoid (Detralex), methotrexate, and their combination. Ann N Y Acad Sci. 2009;1173:798-804.
Rovenský, J., Stancíková, M., Rovenská, E., Stvrtina, S., Stvrtinová, V., & Svík, K. (2009). Treatment of rat adjuvant arthritis with flavonoid (Detralex), methotrexate, and their combination. Annals of the New York Academy of Sciences, 1173, 798-804. https://doi.org/10.1111/j.1749-6632.2009.04618.x
Rovenský J, et al. Treatment of Rat Adjuvant Arthritis With Flavonoid (Detralex), Methotrexate, and Their Combination. Ann N Y Acad Sci. 2009;1173:798-804. PubMed PMID: 19758231.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Treatment of rat adjuvant arthritis with flavonoid (Detralex), methotrexate, and their combination. AU - Rovenský,Jozef, AU - Stancíková,Mária, AU - Rovenská,Emília, AU - Stvrtina,Svetoslav, AU - Stvrtinová,Viera, AU - Svík,Karol, PY - 2009/9/18/entrez PY - 2009/9/18/pubmed PY - 2009/10/30/medline SP - 798 EP - 804 JF - Annals of the New York Academy of Sciences JO - Ann. N. Y. Acad. Sci. VL - 1173 N2 - In both adjuvant arthritis and rheumatoid arthritis, edema and inflammation appear in synovial joints. Edema or effusion reflects an imbalance in lymph dynamics. Purified micronized flavonoid fraction is mainly used in the treatment of chronic venous insufficiency. This compound improves lymphatic drainage with a significant increase in lymphatic flow and lymphatic pulsality. It is suggested that the beneficial effect of purified micronized flavonoid fraction may be involved in the treatment of adjuvant arthritis in rats. In this study treatment of adjuvant arthritis in rats with Detralex, methotrexate, and their combination were evaluated. Groups of rats with adjuvant arthritis were treated with methotrexate (0.6 mg/kg/week), Detralex (20 mg/kg/day), and their combination for 50 days from adjuvant application. Hind paw swelling, arthrogram scores, serum albumin level, serum nitrite/nitrate concentrations, and whole-body mineral density were evaluated as markers of inflammation and destructive changes associated with arthritis. Long-term prophylactic treatment with low-dose methotrexate significantly inhibited the markers of both inflammation and arthritis. Detralex administered alone slightly decreased both the hind paw swelling and the arthritic score. Other inflammatory and arthritic markers were not significantly influenced. However, Detralex combined with methotrexate markedly potentiated the beneficial effects of methotrexate, which resulted in a more significant reduction in hind paw swelling, arthritic scores, and serum concentrations of nitrite/nitrate. Interestingly, the arthritis-induced decrease of bone mineral density in AA rats was significantly lower only in the group treated with the combination of Detralex and methotrexate. Our results indicate that Detralex increased the therapeutic efficacy of methotrexate basal treatment in AA. We suggest that this may be related to the beneficial effect of Detralex on microcirculation, especially on venules and lymphatic vessels. SN - 1749-6632 UR - https://www.unboundmedicine.com/medline/citation/19758231/Treatment_of_rat_adjuvant_arthritis_with_flavonoid__Detralex__methotrexate_and_their_combination_ L2 - https://doi.org/10.1111/j.1749-6632.2009.04618.x DB - PRIME DP - Unbound Medicine ER -